Match tier Likely match
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Leihong Wu

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Staff Fellow

Also affiliated: Qingdao University (2020); Zhejiang Chinese Medical University (2011); United States Food and Drug Administration (2015–2025); Center for Devices and Radiological Health (2021); Zhejiang University of Science and Technology (2011); Government of the United States of America (2021); Cancer Research And Biostatistics (2024); Food and Drug Administration (2016–2020); Zhejiang University (2010–2014)

Staff Researcher

25 h-index 110 pubs 2,505 cited

  • Humans
  • Artificial Intelligence
  • Drug Labeling
  • United States Food and Drug Administration
  • Drug-Related Side Effects and Adverse Reactions
  • United States
  • Animals
  • Benchmarking
  • Reproducibility of Results
  • High-Throughput Nucleotide Sequencing
  • Pharmaceutical Preparations
  • Chemical and Drug Induced Liver Injury
  • Machine Learning
  • Male
  • Oligonucleotide Array Sequence Analysis

Biography and Research Information

OverviewAI-generated summary

Leihong Wu's research focuses on the application of artificial intelligence and machine learning in regulatory science, particularly within the fields of toxicology and bioinformatics. Wu investigates the use of deep learning models for predictive toxicology, analyzing large datasets such as those from the Tox21 initiative to understand the trade-offs between prediction accuracy and model explainability. This work aims to advance the development of more reliable computational methods for assessing chemical and drug safety.

Further research involves the application of natural language processing (NLP) techniques to analyze complex biomedical documents, such as drug labeling information. Wu has explored BERT-based NLP models for classifying drug-induced liver injury risks and has investigated text summarization using advanced models like ChatGPT for drug labeling documents. These efforts contribute to improving the efficiency and accuracy of information extraction from regulatory texts.

Wu's work also extends to genomics and sequencing analysis, with publications evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology and assessing cancer mutation detection methods. Wu leads a research group and has a significant publication record, with 110 total publications and an h-index of 25, indicating a highly cited researcher. Key collaborators include Joshua Xu, Magnus Gray, and Weida Tong, all from the National Center for Toxicological Research.

Metrics

  • h-index: 25
  • Publications: 110
  • Citations: 2,505

Selected Publications

  • GANomics: bridging legacy and modern transcriptomic platforms for clinical applications (2026)
    npj Genomic Medicine DOI OpenAlex
  • Comparative Study of Molecular Descriptors and AI-Based Embeddings for Toxicity Prediction (2025)
    Chemical Research in Toxicology 1 citation DOI OpenAlex
  • Benchmarking bias in embeddings of healthcare AI models: using SD-WEAT for detection and measurement across sensitive populations (2025)
    BMC Medical Informatics and Decision Making 2 citations DOI OpenAlex
  • Assessing the developmental effects of fentanyl and impacts on lipidomic profiling using neural stem cell models (2025)
    Experimental Biology and Medicine 2 citations DOI OpenAlex
  • Biomarkers of Neurotoxicity and Disease (2025)
    Elsevier eBooks 1 citation DOI OpenAlex
  • Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabel (2025)
    Drug Safety 15 citations DOI OpenAlex
  • Is ChatGPT Ready for Public Use in Organ-Specific Drug Toxicity Research? (2025)
    Drug Discovery Today 2 citations DOI OpenAlex
  • Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1 (2024)
    Experimental Biology and Medicine 4 citations DOI OpenAlex
  • Enhancing Bias Assessment for Complex Term Groups in Language Embedding Models: Quantitative Comparison of Methods (2024)
    JMIR Medical Informatics 2 citations DOI OpenAlex
  • Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA Labeling (2024)
    Drug Safety 9 citations DOI OpenAlex
  • Assessing the performance of large language models in literature screening for pharmacovigilance: a comparative study (2024)
    Frontiers in Drug Safety and Regulation 16 citations DOI OpenAlex
  • SD-WEAT: Towards Robustly Measuring Bias in Input Embeddings (2024)
    Communications in computer and information science DOI OpenAlex
  • Text summarization with ChatGPT for drug labeling documents (2024)
    Drug Discovery Today 16 citations DOI OpenAlex
  • PERform: assessing model performance with predictivity and explainability readiness formula (2024)
    Journal of Environmental Science and Health Part C 2 citations DOI OpenAlex
  • A framework enabling LLMs into regulatory environment for transparency and trustworthiness and its application to drug labeling document (2024)
    Regulatory Toxicology and Pharmacology 13 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

179 Collaborators 75 Institutions 13 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics